Tonix director granted 22,700 stock options
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. director Adeoye Y Olukotun reported receiving a stock option grant covering 22,700 shares of common stock. The option has an exercise price of $13.28 per share and expires on May 12, 2036. It was granted under the company’s 2026 Stock Incentive Plan and vests on the earlier of the one-year anniversary of the grant date or the 2027 Annual Meeting of Stockholders. Following this grant, Olukotun holds stock options for 22,700 underlying shares directly.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option | 22,700 | $0.00 | $0.00 |
Footnotes (1)
- F1. The option was granted pursuant to the Issuer's 2026 Stock Incentive Plan and vests on the earlier of the one year anniversary of the grant date and the Issuer's 2027 Annual Meeting of Stockholders.
Key Figures
Key Terms
Stock Option financial
2026 Stock Incentive Plan financial
Annual Meeting of Stockholders financial
Grant, award, or other acquisition financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tonix Pharmaceuticals (TNXP) director Adeoye Y Olukotun acquire in this Form 4?
What is the exercise price of the TNXP stock options granted to Adeoye Y Olukotun?
When do the TNXP stock options granted to Adeoye Y Olukotun vest?
When do Adeoye Y Olukotun’s Tonix Pharmaceuticals stock options expire?
Under what plan were the TNXP stock options for Adeoye Y Olukotun granted?
AI-generated analysis. How Rhea-AI works. Not financial advice.